Prescrire has responded to a consultation by the European Medicines Agency (EMA) on the acceptability of proprietary drug names. In March 2022, Prescrire responded. to a public consultation by the European Medicines Agency (EMA) concerning the 7th revision of the guideline on the acceptability of names for medicinal products authorised through the European centralised procedure (1,2). The brand name of a drug can have harmful consequences if it increases the risk of error or confusion. Prescrire therefore closely monitors the policies for prevention of these avoidable errors put in place by drug regulatory agencies, particularly in Europe.
展开▼
